Market closed

Travere Therapeutics/$TVTX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Ticker

$TVTX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

380

Website

www.travere.com

TVTX Metrics

BasicAdvanced

$1.5B

-

-$4.55

0.71 -

Price and volume

Market cap

$1.5B

Beta

0.71

52-week high

$19.37

52-week low

$5.12

Average daily volume

1.2M

Financial strength

Current ratio

1.709

Quick ratio

1.606

Long term debt to equity

-1,078.801

Total debt to equity

-1,321.449

Interest coverage (TTM)

-25.00%

Management effectiveness

Return on assets (TTM)

-26.14%

Return on equity (TTM)

-279.94%

Valuation

Price to revenue (TTM)

6.48

Price to book

-43.67

Price to tangible book (TTM)

-9.88

Price to free cash flow (TTM)

-3.569

Growth

Revenue change (TTM)

57.08%

Earnings per share change (TTM)

272.21%

3-year revenue growth (CAGR)

-2.75%

3-year earnings per share growth (CAGR)

1.36%

What the Analysts think about TVTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.

TVTX Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

TVTX Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

TVTX News

AllArticlesVideos

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1 week ago

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Seeking Alpha·4 weeks ago

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

GlobeNewsWire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TVTX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Travere Therapeutics stock?

Travere Therapeutics (TVTX) has a market cap of $1.5B as of January 15, 2025.

What is the P/E ratio for Travere Therapeutics stock?

The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of January 15, 2025.

Does Travere Therapeutics stock pay dividends?

No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Travere Therapeutics dividend payment date?

Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Travere Therapeutics?

Travere Therapeutics (TVTX) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.